It seems we drifted or pivoted from this original work on tumours, to blood bourne cancers, then ultimately in a completely new direction to the eye. This was why i always figured the problem was maybe that intravenous application was too non specific outside of mouse model and they were struggling to hit desired target in larger primates. I was not sure why pyc decided direct tumour injection was of no commercial interest? At the moment some poor souls spend enormous amounts on therapies just to extend life rather than to cure. Surely there would be value? Ultimately needs to be funded but is a treatment for such a relatively rare eye disease going to fund much else for pyc, other than share price maybe.
PYC Price at posting:
6.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)